Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey | Zendy

AnneGeneviève Marcelin | Zendy; Charlotte Charpentier | Zendy; Pantxika Bellecave | Zendy; Basma Abdi | Zendy; MarieLaure Chaix | Zendy; Virginie Ferré | Zendy; Stéphanie Raymond | Zendy; Djeneba Fofana | Zendy; Laurence Bocket | Zendy; Audrey Mirand | Zendy; Hélène Le GuillouGuillemette | Zendy; Brigitte Montès | Zendy; Corinne Amiel | Zendy; Coralie Pallier | Zendy; Samira FafiKremer | Zendy; Anne De Monte | Zendy; Élodie Alessandri-Gradt | Zendy; Caroline Scholtès | Zendy; Anne Maillard | Zendy; Hélène Jeulin | Zendy; Magali BouvierAlias | Zendy; Catherine Roussel | Zendy; Georges Dos Santos | Zendy; Anne Signori-Schmück | Zendy; Julia Dina | Zendy; Sophie Vallet | Zendy; Karl Stéfic | Zendy; Cathia Soulié | Zendy; Vincent Cálvez | Zendy; Diane Descamps | Zendy; Philippe Flandre | Zendy; Alexandra Ducancelle | Zendy; Laurence Courdavault | Zendy; C Alloui | Zendy; P. Honoré | Zendy; Quentin Lepiller | Zendy; Dominique Bettinger | Zendy; P. Pinson-Recordon | Zendy; Camille Tumiotto | Zendy; Sandrine Reigadas | Zendy; Christopher Payan | Zendy; J C Duthé | Zendy; M. Leroux | Zendy; J. Dina | Zendy; Astrid Vabret | Zendy; C Henquell | Zendy; A Simohamed | Zendy; Fort de G Dos Santos | Zendy; Sabine Yerly | Zendy; C Gaille | Zendy; W Caveng | Zendy; S. Chapalay | Zendy; Alexandra Calmy | Zendy; Patrice Morand | Zendy; HU Paris | Zendy; C. Pallier | Zendy; Mariem Raho-Moussa | Zendy; M.Leonard Mole | Zendy; M.-J. Dulucq | Zendy; Enag Kazali Alidjinou | Zendy; Sylvie RangerRogez | Zendy; MaryAnne Trabaud | Zendy; V. Icard | Zendy; J. C. Tardy | Zendy; Catherine Tamalet | Zendy; Catherine Delamare | Zendy; Évelyne Schvoerer | Zendy; Honorine Fenaux | Zendy; Audrey Rodallec | Zendy; Elisabeth AndréGarnier | Zendy; Aurélie Guigon | Zendy; Jérôme Guinard | Zendy; C. Charpentier | Zendy; Benoît Visseaux | Zendy; Gilles Peytavin | Zendy; M.P. Fillion | Zendy; Isabelle Malet | Zendy; Marc Wirden | Zendy; Lambert Assoumou | Zendy; Dominique Costagliola | Zendy; Laurence MorandJoubert | Zendy; Sidonie Lambert-Niclot | Zendy; Constance Delaugerre | Zendy; Nadia Mahjoub | Zendy; G. Giraudeau | Zendy; A. BebyDefaux | Zendy; D Plainchamp | Zendy; M Léoz | Zendy; JeanChristophe Plantier | Zendy; Pierre Gantner | Zendy; Patricia Fischer | Zendy; Jacques Izopet | Zendy; Juan Guido Chiabrando | Zendy; Francis Barin | Zendy; G Fajole | Zendy; O Burgault | Zendy; S. Marque Juillet | Zendy

Open Access

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey

Author(s) -

AnneGeneviève Marcelin,

Charlotte Charpentier,

Pantxika Bellecave,

Basma Abdi,

MarieLaure Chaix,

Virginie Ferré,

Stéphanie Raymond,

Djeneba Fofana,

Laurence Bocket,

Audrey Mirand,

Hélène Le GuillouGuillemette,

Brigitte Montès,

Corinne Amiel,

Coralie Pallier,

Samira FafiKremer,

Anne De Monte,

Élodie Alessandri-Gradt,

Caroline Scholtès,

Anne Maillard,

Hélène Jeulin,

Magali BouvierAlias,

Catherine Roussel,

Georges Dos Santos,

Anne Signori-Schmück,

Julia Dina,

Sophie Vallet,

Karl Stéfic,

Cathia Soulié,

Vincent Cálvez,

Diane Descamps,

Philippe Flandre,

Alexandra Ducancelle,

Laurence Courdavault,

C Alloui,

P. Honoré,

Quentin Lepiller,

Dominique Bettinger,

P. Pinson-Recordon,

Camille Tumiotto,

Sandrine Reigadas,

Christopher Payan,

J C Duthé,

M. Leroux,

J. Dina,

Astrid Vabret,

C Henquell,

A Simohamed,

Fort de G Dos Santos,

Sabine Yerly,

C Gaille,

W Caveng,

S. Chapalay,

Alexandra Calmy,

Patrice Morand,

HU Paris,

C. Pallier,

Mariem Raho-Moussa,

M.Leonard Mole,

M.-J. Dulucq,

Enag Kazali Alidjinou,

Sylvie RangerRogez,

MaryAnne Trabaud,

V. Icard,

J. C. Tardy,

Catherine Tamalet,

Catherine Delamare,

Évelyne Schvoerer,

Honorine Fenaux,

Audrey Rodallec,

Elisabeth AndréGarnier,

Aurélie Guigon,

Jérôme Guinard,

C. Charpentier,

Benoît Visseaux,

Gilles Peytavin,

M.P. Fillion,

Isabelle Malet,

Marc Wirden,

Lambert Assoumou,

Dominique Costagliola,

Laurence MorandJoubert,

Sidonie Lambert-Niclot,

Constance Delaugerre,

Nadia Mahjoub,

G. Giraudeau,

A. BebyDefaux,

D Plainchamp,

M Léoz,

JeanChristophe Plantier,

Pierre Gantner,

Patricia Fischer,

Jacques Izopet,

Juan Guido Chiabrando,

Francis Barin,

G Fajole,

O Burgault,

S. Marque Juillet

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab193

Subject(s) - dolutegravir , raltegravir , integrase , integrase inhibitor , tolerability , elvitegravir , regimen , drug resistance , virology , univariate analysis , medicine , genotype , multivariate analysis , pharmacology , human immunodeficiency virus (hiv) , viral load , biology , genetics , adverse effect , antiretroviral therapy , gene

Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance development/re-emergence, compared with 3DRs, is thus of paramount importance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research